Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The arimidex, tamoxifen alone or in combination (ATAC) trial is a large-scale, international, industry-sponsored interventional, randomized study involving almost 10,000 early-stage postmenopausal breast cancer patients who were randomized to receive either anastrozole alone or in combination with tamoxifen, or tamoxifen alone.

Anastrozole Update: Superior Clinical Efficacy